Antibody Therapeutics Conference 2019
New Generation Immunotherapy: from Discovery to Development
(CAR-T, ADC, Immuno-Oncology)
Venue: 南港六福萬怡酒店超新星廳 (台北市南港區忠孝東路七段359號7樓）
Time: 2019 / 11 / 7 (四）- 11 / 8 (五)
活動網站：活動網站連結
>>>報名網址：報名網址連結
台灣抗體協會將於2019年11月7-8日(星期四下午、星期五全日)於南港六福萬怡酒店超新星廳(台北市南港區忠孝東路七段359號7樓)舉辦「2019 AntibodyTherapeutics ConferenceNew Generation Immunotherapy: from Discovery to Development!」，將聚焦CAR-T, ADC, Immuno-Oncology等領域，邀請海內外學者共同談討，齊聚一堂。
抗體協會自2013年舉辦第一屆ATC論壇，自今已邁入第七個年頭，往年皆吸引超過300人與會。這幾年各國皆如火如荼地投如抗體治療的應用與開發，也有不少成功的進程，台灣當然也不例外，可以感受到產、官、學、研積極投入。除了新標的抗體的開發，如何有效連結產業鏈，成為台灣學研機構共同面臨的課題。我們邀請國內外專家發表專題演講，以期激發跨界討論與合作火花，竭誠邀請各界先進共襄盛舉。
講者簡介：
♦ Bryan D. Choi, MD, PhD
Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA / Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
♦ Yu-Hsiang Chang ,MD, Ph.D.
Tai Chen Stem Cell Therapy Center, National Taiwan University Hospital
♦ Shao Chih Chiu, Ph.D.
Graduate Institute of Biomedical Sciences, China Medical University , Center for Cell Therapy, China Medical University Hospital
♦ Ming-Tain Lai, Ph.D.
Chief Scientific Officer, OBI Pharma, Inc.
♦ Simon Shih-Hsien Chuang, Ph.D.
Director, Development Center for Biotechnology, Medicinal Chemistry Department, Institute of Pharmaceutics
♦ Keng-Li Lan, M.D., Ph.D.
Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital
♦ Cheng-I Wang, Ph.D.
Head of the human monoclonal antibody technology platform, Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR)
議程：
11/7 Thursday
|
Time |
Topic and Speaker |
|
|---|---|---|
|
13:30-14:00 |
Registration |
|
|
14:00-14:10 |
Opening Remarks 甘良生 理事長 Lawrence Gan, Ph.D 紀威光 副執行長 Wei-kuang Chi, Ph.D. |
|
|
14:10-14:15 |
Chimeric Antigen Receptor T Cells (CAR-T) Moderator：官建村 博士 Chien-Tsun Kuan i, Ph.D. EVP/ COO & CTO, GenomeFrontier Therapeutics, Inc. |
|
|
14:15-15:05 |
Keynote Speaker Bryan D. Choi, MD, PhD Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA / Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA |
|
|
15:05-15:45 |
CAR-T Cell Therapy for B-cell malignancies 張裕享 醫師 Yu-Hsiang Chang ,MD, Ph.D. Tai Chen Stem Cell Therapy Center, National Taiwan University Hospital |
|
|
15:45-16:15 |
Break |
|
|
16:15-16:55 |
Multiple carcinoma targetable CAR for immune cell therapy 邱紹智 博士 Shao Chih Chiu, Ph.D. Graduate Institute of Biomedical Sciences, China Medical University , Center for Cell Therapy, China Medical University Hospital |
|
|
16:55-17:00 |
Closing Remarks |
|
11/8 Friday
|
Time |
Topic and Speaker |
|
|---|---|---|
|
9:00-9:15 |
Registration |
|
|
9:15-9:20 |
Antibody-drug conjugates (ADC) Moderator：劉理成 總經理 Lee Cheng Liu, Ph.D. President/CEO, EirGenix Inc. |
|
|
9:20-10:10 |
Keynote Speaker (邀請中) |
|
|
10:10-10:50 |
賴明添 博士 Ming-Tain Lai, Ph.D. Chief Scientific Officer, OBI Pharma, Inc. |
|
|
10:50-11:20 |
Break |
|
|
11:20-12:00 |
Site-specific trimannosyl conjugation and ADC capability in DCB 莊士賢 博士 Simon Shih-Hsien Chuang, Ph.D. Director, Development Center for Biotechnology, Medicinal Chemistry Department, Institute of Pharmaceutics |
|
|
12:00-12:05 |
Closing Remarks |
|
|
12:05-12:10 |
Taiwan Antibody Association Members Meeting |
|
|
12:10-14:00 |
Lunch |
|
|
14:00-14:05 |
Immuno-Oncology (IO) Moderator：吳忠勳 執行長 Chung-Hsiun Herbert Wu, Ph.D. CEO, Development Center for Biotechnology |
|
|
14:05-14:45 |
Tumor localized immunotherapy 藍耿立 醫師 Keng-Li Lan, M.D., Ph.D. Associate Professor, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University; Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital |
|
|
14:45-15:25 |
(邀請中) |
|
|
15:25-15:55 |
Break |
|
|
15:55-16:45 |
Keynote Speaker Engineering cancer immunotherapy Cheng-I Wang, Ph.D. Head of the human monoclonal antibody technology platform, Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR) |
|
|
16:45-16:50 |
Closing Remarks |
|
主辦單位保留活動變更權力
網路報名費用（請於下方完成報名及繳費）：
TAA會員：1500元 / 一般報名：2000元
TAA學生會員：800元 / 一般學生報名：1200元（學生報名需於現場出示學生證明）
※現場報名一律2000元
下列團體會員報名皆享會員價（報名時需提供公司 email 寄送確認信）：
中央研究院 / 中天生物科技股份有限公司 / 台康生技股份有限公司 / 台灣醣聯生技醫藥股份有限公司 / 永昕生物醫藥股份有限公司 / 生達化學製藥股份有限公司 / 全福生物科技股份有限公司 / 免疫功坊股份有限公司 / 抗體王生物科技股份有限公司 / 奇異亞洲醫療設備股份有限公司 / 泉盛生物科技股份有限公司 / 財團法人生物技術開發中心 / 國光生物科技股份有限公司 / 基亞生物科技股份有限公司 / 智合精準醫學科技股份有限公司 / 進階生物科技股份有限公司 /圓祥生命科技股份有限公司
主辦單位：
連絡電話：台灣抗體協會秘書處 孫先生 (02)77003800 #5216 ericsun@dcb.org.tw